Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 36.9%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant drop in short interest in January. As of January 30th, there was short interest totaling 1,603 shares, a drop of 36.9% from the January 15th total of 2,541 shares. Based on an average daily trading volume, of 22,976 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the shares of the company are sold short. Currently, 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 22,976 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Ratings Changes

A number of research firms have weighed in on BOLT. HC Wainwright set a $7.00 price target on shares of Bolt Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, October 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, January 21st. Finally, Zacks Research cut shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $34.00.

Bolt Biotherapeutics Stock Down 1.6%

Shares of NASDAQ BOLT opened at $4.92 on Friday. The company has a market cap of $9.45 million, a price-to-earnings ratio of -0.22 and a beta of 0.92. The company has a current ratio of 3.57, a quick ratio of 3.57 and a debt-to-equity ratio of 0.65. Bolt Biotherapeutics has a 12 month low of $4.41 and a 12 month high of $10.50. The stock has a 50-day moving average price of $5.76 and a two-hundred day moving average price of $5.49.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($3.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.07) by $1.35. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $0.82 million. As a group, analysts forecast that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC increased its holdings in Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares in the last quarter. Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics during the third quarter worth about $85,000. Susquehanna International Group LLP acquired a new position in shares of Bolt Biotherapeutics in the third quarter valued at approximately $89,000. Nano Cap New Millennium Growth Fund L P bought a new position in Bolt Biotherapeutics in the 4th quarter valued at approximately $112,000. Finally, T3 Companies LLC acquired a new stake in Bolt Biotherapeutics during the 4th quarter worth approximately $208,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.